Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Boerhaave’s syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report
Journal of cardiothoracic surgery, 2026
Impact of Preoperative Semaglutide Discontinuation Timing on Postoperative Outcomes in Aesthetic Abdominoplasty: A Retrospective Comparative Study
Aesthetic plastic surgery, 2026
Real-world and computational identification of herbal candidates associated with adverse event patterns in glucagon-like peptide-1 therapy for obesity
Scientific reports, 2026
Late-stage generation of 14C/3H-radiolabeled lysine residues via hydroformylation of peptides
Nature communications, 2026
GLP-1 Agonists in Adolescent Obesity: A Narrative Review of Single, Dual, and Triple Agonists
Diabetes, metabolic syndrome and obesity : targets and therapy, 2026;19:566414
Semaglutide and major adverse cardiovascular events in patients with and without DM: A systematic review and meta-analysis
Biomedical reports, 2026;25(2):92
Personalized Combination of a Ketogenic Diet and Low-Dose Semaglutide for Cardiometabolic Health: A Retrospective Case Series
Journal of personalized medicine, 2026;16(6)
Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use
JAAD case reports, 2026;74:247-250
Sustained Glycaemic Control and Preserved Beta-Cell Function in Newly Diagnosed Type 1 Diabetes Treated With Semaglutide
Diabetes/metabolism research and reviews;42(5):e70191
Towards Sustainable Synthesis of Peptide Therapeutics via Tag-Assisted Peptide Synthesis and Aryl Selenoester Aminolysis Ligation
Journal of the American Chemical Society, 2026
GLP-1-based therapy and ICD-10-documented heart failure or respiratory failure events in non-diabetic adults with rheumatoid arthritis and obesity: a TriNetX federated cohort study
Clinical rheumatology, 2026
Clinical evidence of semaglutide for metabolic dysfunction-associated steatotic liver disease (MASLD): An updated meta-analysis
British journal of clinical pharmacology, 2026
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity
Arthritis & rheumatology (Hoboken, N.J.), 2026
Perinatal Semaglutide Treatment Improves Maternal Health and Mitigates Offspring Metabolic Dysfunction in a Mouse Model of Maternal Obesity
bioRxiv : the preprint server for biology, 2026
Semaglutide Selectively Improves Metabolic and Cognitive Function in 5xFAD Mice
International journal of molecular sciences, 2026;27(12)
Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro)
Cureus, 2026;18(6):e110692
[Pharmacological treatment of obstructive sleep apnea syndrome]
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova;126(5. Vyp. 2):48-54
SGLT2 inhibitors and incretin-based therapies for metabolic dysfunction-associated steatohepatitis: a systematic review
European journal of clinical pharmacology, 2026;82(7)
GLP-1 receptor agonist adjunct therapy stabilises Ramadan dysglycaemia in insulin-treated diabetes: a CGM-based study
Diabetes research and clinical practice, 2026;:113369
Cost-effectiveness of semaglutide versus dulaglutide for Type 2 Diabetes in China: A Markov Model analysis
PloS one, 2026;21(6):e0351059